Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iguratimod in diffuse cutaneous systemic sclerosis
NCT04515706Unknown
- Sponsor
- Renji Hospital
- Start
- Jan 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of iguratimod in systemic sclerosis (SSc), sponsored by Renji Hospital. Primary endpoint: Number of Participants Who Experience Grade 3 or Higher Adverse Events at 24 weeks. Status: unknown.
02
Drugs
iguratimod
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT04515706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04515706.